Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction (TSTENT)
Primary Purpose
Hydronephrosis; Obstruction, Ureter, Renal Failure, Malignancy
Status
Not yet recruiting
Phase
Phase 3
Locations
Israel
Study Type
Interventional
Intervention
ureteral stent\s insertion
Sponsored by
About this trial
This is an interventional treatment trial for Hydronephrosis; Obstruction, Ureter
Eligibility Criteria
Inclusion Criteria: patient with malignant ureteral obstruction Exclusion Criteria: ureteral obstruction of other causes Language comprehension or other limitation in giving informed consent
Sites / Locations
- Rabin Medical Center
- Sheba medical center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
single silicone stent
Tandem polyurethane stents
Arm Description
patients with malignant ureteral obstruction that was treated by single large-caliber 8-12Fr silicone stent
patients with malignant ureteral obstruction that was treated by tandem 6 Fr Percuflex™ stents
Outcomes
Primary Outcome Measures
stent failure rate
Failure will be defined when two of the following three appear: renal colic, rise in serum creatinine, hydronephrosis
Secondary Outcome Measures
quality of life
using the Ureteral stent symptom questionnaire (USSQ) score
overall survival
overall survival
Full Information
NCT ID
NCT05992363
First Posted
August 8, 2023
Last Updated
August 8, 2023
Sponsor
Rabin Medical Center
Collaborators
Sheba Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT05992363
Brief Title
Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction
Acronym
TSTENT
Official Title
Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 2023 (Anticipated)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
December 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rabin Medical Center
Collaborators
Sheba Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Malignant ureteral obstruction (MUO) is an extrinsic ureteral obstruction caused by malignant diseases. This study aim to compare tandem 6 Fr Percuflex™ stents and single large-caliber 8Fr silicone stent in patients with MUO. The primary endpoint is stent failure rate. The secondary endpoints are patient comfort, quality of life and overall survival.
Detailed Description
Malignant ureteral obstruction (MUO) is an extrinsic ureteral obstruction caused by malignant diseases. MUO may induce renal failure, which would be a barrier to several therapies including chemotherapy. Indwelling double-pigtail polymeric ureteral stent is a common method to release renal obstruction, but does not necessarily guarantee renal decompression as most studies reported stent failure with a mean of 30% at a mean time of three months [1-3]. Various endoscopic strategies have been proposed to increase time to failure, including tandem polymeric stents, metallic spiral coil stent, self-expanding Nitinol stent and polymeric stents with different lumen diameter and stiffness [4-7]. However, heterogeneity of MUO, low number of patients, unspecified polymer type, retrospective studies and the lack of a standard method to assess stent failure limit robust comparative analysis.
Tandem ureteral stents (TUS) technique uses two polymeric ureteral stents passed simultaneously to better withstand the presumed compressive forces that overcome conventional single stent. This method offers an additional parallel lumen and allows more extraluminal flow between the two stents [6].
In a study on TUS in 39 renal units with MUO, two 6 Fr stents were inserted. Stent failure, defined by flank pain with increasing creatinine level or worsening hydronephrosis during 3 months after stents insertion, was occurred in 4% of cases [7]. This low failure rate compares favorably with the reported rates with single 6Fr polymeric stent or metallic stent. However, stents irritation, defined by profound lower urinary tract symptoms or renal colic in the absence of worsening hydronephrosis or infection, was reported in 29-85% of patients [7,8].
Silicon stent, which is considered biocompatible and soft, has the potential to be less irritative. In a recent systematic review, silicone stents has less stent-related symptoms in comparison to non-silicone polymers and ''hard'' stents. [9]. However, silicone has high susceptibility to compression, which in case of MUO may results in lower drainage efficacy.
This study aim to compare tandem 6 Fr Percuflex™ stents and single large-caliber 8Fr silicone stent in patients with MUO. The primary endpoint is stent failure rate. The secondary endpoints are patient comfort, quality of life and overall survival.
References:
Docimo SG, Dewolf WC. High failure rate of indwelling ureteral stents in patients with extrinsic obstruction: experience at 2 institutions. J Urol. 1989;142(2 Pt 1):277-279. doi:10.1016/s0022-5347(17)38729-3
Vogt B, Blanchet LH. Analysis of Ureteral Tumour Stents for Malignant Ureteral Obstruction: Towards Reshaping an Optimal Stent. Res Rep Urol. 2021;13:773-782. Published 2021 Oct 27. doi:10.2147/RRU.S334277
Chung SY, Stein RJ, Landsittel D, et al. 15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents. J Urol. 2004;172(2):592-595. doi:10.1097/01.ju.0000130510.28768.f5
Patel C, Loughran D, Jones R, Abdulmajed M, Shergill I. The resonance® metallic ureteric stent in the treatment of chronic ureteric obstruction: a safety and efficacy analysis from a contemporary clinical series. BMC Urol. 2017;17(1):16. Published 2017 Mar 10. doi:10.1186/s12894-017-0204-8
Khoo CC, Ho C, Palaniappan V, et al. Single-Center Experience with Three Metallic Ureteral Stents (Allium® URS, Memokath™-051, and Resonance®) for Chronic Ureteral Obstruction. J Endourol. 2021;35(12):1829-1837. doi:10.1089/end.2021.0208
Fromer DL, Shabsigh A, Benson MC, Gupta M. Simultaneous multiple double pigtail stents for malignant ureteral obstruction. Urology. 2002;59(4):594-596. doi:10.1016/s0090-4295(01)01646-7
Elsamra SE, Motato H, Moreira DM, et al. Tandem ureteral stents for the decompression of malignant and benign obstructive uropathy. J Endourol. 2013;27(10):1297-1302. doi:10.1089/end.2013.0281
Shvero A, Haifler M, Mahmud H, Dotan Z, Winkler H, Kleinmann N. Quality of life with tandem ureteral stents compared to percutaneous nephrostomy for malignant ureteral obstruction. Support Care Cancer. 2022;30(11):9541-9548. doi:10.1007/s00520-022-07354-2
Boeykens M, Keller EX, Bosio A, et al. Impact of Ureteral Stent Material on Stent-related Symptoms: A Systematic Review of the Literature. Eur Urol Open Sci. 2022;45:108-117. Published 2022 Oct 19. doi:10.1016/j.euros.2022.09.005
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hydronephrosis; Obstruction, Ureter, Renal Failure, Malignancy, Ureter Obstruction, Ureter Stricture
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
106 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
single silicone stent
Arm Type
Active Comparator
Arm Description
patients with malignant ureteral obstruction that was treated by single large-caliber 8-12Fr silicone stent
Arm Title
Tandem polyurethane stents
Arm Type
Active Comparator
Arm Description
patients with malignant ureteral obstruction that was treated by tandem 6 Fr Percuflex™ stents
Intervention Type
Device
Intervention Name(s)
ureteral stent\s insertion
Intervention Description
ureteral stent\s insertion in the operating room
Primary Outcome Measure Information:
Title
stent failure rate
Description
Failure will be defined when two of the following three appear: renal colic, rise in serum creatinine, hydronephrosis
Time Frame
1 year
Secondary Outcome Measure Information:
Title
quality of life
Description
using the Ureteral stent symptom questionnaire (USSQ) score
Time Frame
1 year
Title
overall survival
Description
overall survival
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patient with malignant ureteral obstruction
Exclusion Criteria:
ureteral obstruction of other causes
Language comprehension or other limitation in giving informed consent
Facility Information:
Facility Name
Rabin Medical Center
City
Petah Tikva
ZIP/Postal Code
49414
Country
Israel
Facility Name
Sheba medical center
City
Ramat Gan
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ari Luder, MD
Phone
+972527812580
Email
ariluder@yahoo.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction
We'll reach out to this number within 24 hrs